Carbidopa News and Research

RSS
Study shows how gut bacteria affect the treatment of Parkinson's disease

Study shows how gut bacteria affect the treatment of Parkinson's disease

FDA approves drug as add-on treatment for Parkinson's disease patients

FDA approves drug as add-on treatment for Parkinson's disease patients

NeuroDerm starts patient enrollment in long-term safety study of ND0612 for treatment of Parkinson’s disease

NeuroDerm starts patient enrollment in long-term safety study of ND0612 for treatment of Parkinson’s disease

Aerobic exercise training may slow progression of Parkinson's disease

Aerobic exercise training may slow progression of Parkinson's disease

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

FDA awards research grants to boost product development for patients with rare diseases

FDA awards research grants to boost product development for patients with rare diseases

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

FDA approves RYTARY for Parkinson's disease treatment

FDA approves RYTARY for Parkinson's disease treatment

Impax announces submission of EMA Marketing Authorization Application for IPX066

Impax announces submission of EMA Marketing Authorization Application for IPX066

NeuroDerm signs definitive investment agreements for $16 million financing round

NeuroDerm signs definitive investment agreements for $16 million financing round

Impax resubmits NDA for RYTARY providing updated safety and stability information

Impax resubmits NDA for RYTARY providing updated safety and stability information

NeuroDerm enrolls patients in second ND0612 Phase II clinical trial for treatment of Parkinson's disease

NeuroDerm enrolls patients in second ND0612 Phase II clinical trial for treatment of Parkinson's disease

Mylan, Orion sign settlement, license agreement for generic version of STALEVO

Mylan, Orion sign settlement, license agreement for generic version of STALEVO

NeuroDerm receives MJFF grant to develop ND0612 for treatment of Parkinson's disease

NeuroDerm receives MJFF grant to develop ND0612 for treatment of Parkinson's disease

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

Phase III success with extended-release carbidopa–levodopa formulation

Phase III success with extended-release carbidopa–levodopa formulation

Positive results from NeuroDerm ND0612 Phase I trial on Parkinson's

Positive results from NeuroDerm ND0612 Phase I trial on Parkinson's